

A FLEXIBLE APPROACH TO CUSTOM BUILT RESEARCH

AT QPS WE BELIEVE IN DEVELOPING CLOSE AND LONG-LASTING RELATIONSHIPS WITH OUR CLIENTS. Mutual trust, combined with the agile and flexible approach we offer as a specialty CRO, improves the quality of your outsourced drug development projects.





QPS CORPORATE OVERVIEW

QPS was founded in 1995. Today, the company is considered one of the top CROs in the world. QPS is a GLP/GCP-compliant contract research organization (CRO) supporting discovery, preclinical and clinical drug development. QPS provides quality services to pharmaceutical and biotechnology clients worldwide. Join the many companies that count on QPS' global team of qualified and experienced professionals to deliver drug discovery and development programs in the following service areas:



pharmacology











NEUROPHARMACOLOGY

QPS offers you a vast array of predictive disease models, as well as unparalleled experience with validated transgenic and non-transgenic in vitro and in vivo models covering the majority of pharmacological targets for Alzheimer's, Parkinson's, Huntington's and other neurodegenerative diseases.

TOXICOLOGY

Over the past two decades, QPS has performed thousands of GLP studies for local and international pharmaceutical and biotechnology companies, covering many different disease therapies. This vast experience attests to our ability to effectively deliver high quality toxicology data solutions at our preclinical site in Taiwan.

DMPK

Studies determining Absorption, Distribution, Metabolism and Excretion (ADME) characteristics and QWBA characteristics of drug candidates in laboratory animals are an integral part of the Drug Metabolism and Pharmacokinetics (DMPK) services provided by QPS.





BIOANALYSIS

QPS is built on a worldwide network of resources in bioanalysis for small molecules and biologics, with state of the art facilities in the U.S., Europe and Asia. Find out how a strategic outsourcing alliance with QPS can provide you with world class operational and service excellence.

TRANSLATIONAL MEDICINE

QPS offers specialized biomarker assay capabilities that support the development of targeted therapies and personalized medicines. QPS is a leader in Gene Expression Translation and utilizing Genotyping to accelerate pharmaceutical breakthroughs.

CLINICAL DEVELOPMENT

For more than 20 years, QPS' clinical research sites have collectively completed thousands of clinical trials involving tens of thousands of healthy volunteers and patients. We offer industry-leading early and late phase clinical capabilities, featuring more than 500 Phase I beds across the US, Europe and Asia. Our experience spans complex, First-in-Man, Proof of Concept (POC) programs up to global Phase II-IV studies.



SCIENTIFIC LEADERSHIP AND PROVED RESULTS



Dr. Benjamin M. Chien founded QPS in 1995 to provide high quality bioanalytical LC-MS/MS contract services. Since then, QPS has grown to more than 1,250+ employees in the United States, Europe, India and Asia. Over the years, the company has developed custom-built reserch services, including:

- Preclinical (Toxicology, DMPK and Neuropharmacology)
- ▶ Bioanalysis and Translational Medicine
- ► Clinical Trials (Phase I/IIa)
- ▶ Clinical Research Services (Late Phase Clinical Trials)
- Medical and Regulatory Affairs







OPS IS A GLOBAL CRO WITH LOCATIONS AROUND THE WORLD



BENEFIT FROM THE WORLDWIDE RESOURCES THAT A GLOBAL CONTRACT RESEARCH ORGANIZATION BRINGS

Whether your focus is small molecules, protein biotherapeutics, vaccines, gene therapy or cell therapy, QPS provides a full range of bioanalytical services to support all drug development needs from discovery, through clinical development and regulatory filing.





TIME IS OF THE ESSENCE IN DRUG DEVELOPMENT.
CONTACT THE QPS BUSINESS DEVELOPMENT TEAM TODAY!